There is an urgent need for new treatments that can be used for both the acute and chronic stages of Chagas disease and that are safer and more effective than current treatment regimens, which use benznidazole and nifurtimox.

The oxaborole DNDI-6148 has emerged as a promising lead candidate for visceral leishmaniasis and cutaneous leishmaniasis; it has also shown efficacy against Chagas disease in an in vivo model and its potential for further development is being assessed.

Project updates

2020

A full analysis of the pharmacokinetic, pharmacodynamic, and modelling data to determine the potential for further development of DNDI-6148 was conducted, following its nomination as a clinical candidate for Chagas disease in 2020. Once data is available from Phase I studies in humans (delayed by the COVID-19 pandemic), the analysis will be finalized.